Eli Lilly is paying $100 million upfront for the right to develop CSL’s phase 3-stage IL-6 antibody that had previous...
Eli Lilly paid $100 million upfront for rights to CSL’s phase 3 IL-6 antibody, previously tested for organ transplant rejection after a failed phase 3 study.
Why it mattersCSL's phase 3 IL-6 antibody acquired for $100M upfront prompts reprioritizing repurposing and trial designs.